Colorectal cancer-derived exosomes and modulation KRAS signaling

Clin Transl Oncol. 2022 Nov;24(11):2074-2080. doi: 10.1007/s12094-022-02877-w. Epub 2022 Jul 5.

Abstract

Colorectal cancer (CRC) is one of the most common cancers worldwide and one of the main causes of cancer-associated mortality. At the period of diagnosis, metastases to other tissues will be present in around 30% of CRC individuals. Individuals with CRC continue to have a poor prognosis despite advances in medication. There is a growing body of literature that CRC develops as a result of the aggregation of various mutations in tumor oncogenes or suppressor genes and that diagnosing cancer in its initial phases may assist in increasing the overall lifespan of individuals with the illness. On the other hand, tumor cells may discharge exosomes in response to oncogenic mutations. By Inhibiting signaling pathways, including the Kirsten rat sarcoma virus (KRAS) mechanism, which is important in a variety of cell activities, exosomes have been shown to cause colorectal cancer in animal studies. The purpose of this review was to summarize the latest discoveries on the modulation of KRAS signaling by exosomes extracted from colorectal cancer.

Keywords: Colorectal cancer; Exosome; KRAS; Mutation; Signaling.

Publication types

  • Review

MeSH terms

  • Animals
  • Colorectal Neoplasms* / pathology
  • Exosomes* / metabolism
  • Humans
  • Kirsten murine sarcoma virus / metabolism
  • Mutation
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Proto-Oncogene Proteins p21(ras) / metabolism
  • Signal Transduction

Substances

  • KRAS protein, human
  • Proto-Oncogene Proteins p21(ras)